Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffaele Ornello

Showing results (171-180 of 183) with videos related to

Pageof 19
Sort By:
Journal of the Neurological Sciences|August 7, 2025
Characteristics and causes of recurrent ischemic events in minor ischemic stroke and TIA in the READAPT studyFederico De Santis, Matteo Foschi, Michele Romoli, et al.
European Stroke Journal|February 27, 2026
Impact of cancer on outcomes following breakthrough ischaemic stroke on oral anticoagulants for atrial fibrillation: insights from the ASPERA-R studyMatteo Foschi, Federico De Santis, Francesca Gabriele, et al.
Journal of the American Heart Association|March 31, 2026
Sex Differences in Outcomes After Breakthrough Ischemic Stroke on Oral Anticoagulants for Atrial Fibrillation: An ASPERA-R Inverse Probability Weighted AnalysisMatteo Foschi, Lucio D'Anna, Francesca Gabriele, et al.
Neurology|April 13, 2026
Competing Stroke Etiologies and Outcomes After Breakthrough Ischemic Stroke on Oral Anticoagulants in Patients With Atrial FibrillationMatteo Foschi, Federico De Santis, Francesca Gabriele, et al.
Stroke|March 4, 2021
Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke PreventionMaurizio Paciaroni, Giancarlo Agnelli, Michela Giustozzi, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|June 19, 2026
Early versus Late starting of Direct Oral Anticoagulants after breakthrough ischemic stroke: A Target Trial Analysis from the ASPERA-R StudyLucio D'Anna, Matteo Foschi, Francesca Gabriele, et al.
Neurology|January 28, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA CohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Stroke|May 11, 2022
Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND StudyMaurizio Paciaroni, Valeria Caso, Giancarlo Agnelli, et al.
Cephalalgia : an International Journal of Headache|June 19, 2026
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Neurology|February 19, 2026
Contrast-Associated Acute Kidney Injury After Thrombectomy for Ischemic Stroke: Prognostic Impact and CAN-REST Predictive ScoreGhil Schwarz, Angelo Cascio Rizzo, Gareth Ambler, et al.
Pageof 19

Showing results (171-180 of 183) with videos related to

Sort By:
Pageof 19
Journal of the Neurological Sciences|August 7, 2025
Characteristics and causes of recurrent ischemic events in minor ischemic stroke and TIA in the READAPT studyFederico De Santis, Matteo Foschi, Michele Romoli, et al.
European Stroke Journal|February 27, 2026
Impact of cancer on outcomes following breakthrough ischaemic stroke on oral anticoagulants for atrial fibrillation: insights from the ASPERA-R studyMatteo Foschi, Federico De Santis, Francesca Gabriele, et al.
Journal of the American Heart Association|March 31, 2026
Sex Differences in Outcomes After Breakthrough Ischemic Stroke on Oral Anticoagulants for Atrial Fibrillation: An ASPERA-R Inverse Probability Weighted AnalysisMatteo Foschi, Lucio D'Anna, Francesca Gabriele, et al.
Neurology|April 13, 2026
Competing Stroke Etiologies and Outcomes After Breakthrough Ischemic Stroke on Oral Anticoagulants in Patients With Atrial FibrillationMatteo Foschi, Federico De Santis, Francesca Gabriele, et al.
Stroke|March 4, 2021
Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke PreventionMaurizio Paciaroni, Giancarlo Agnelli, Michela Giustozzi, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|June 19, 2026
Early versus Late starting of Direct Oral Anticoagulants after breakthrough ischemic stroke: A Target Trial Analysis from the ASPERA-R StudyLucio D'Anna, Matteo Foschi, Francesca Gabriele, et al.
Neurology|January 28, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA CohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Stroke|May 11, 2022
Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND StudyMaurizio Paciaroni, Valeria Caso, Giancarlo Agnelli, et al.
Cephalalgia : an International Journal of Headache|June 19, 2026
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Neurology|February 19, 2026
Contrast-Associated Acute Kidney Injury After Thrombectomy for Ischemic Stroke: Prognostic Impact and CAN-REST Predictive ScoreGhil Schwarz, Angelo Cascio Rizzo, Gareth Ambler, et al.
Pageof 19